Strong Q1 2015 Leads To Increasing 12 Month NYSE Price Targets, For Merck

The strong quarter Kenilworth posted last week is causing the bankers to raise their price targets, bit by bit, here. This is CSFB, via Benzinga:

. . . .Neutral, but up to $62 from $60 [12 month price target]. Credit Suisse rated both of those stocks [Lilly and Merck] at Neutral. . . .

I do think Merck is starting to hit its stride, finally — even if CSFB prefers Pfizer at the moment, in the space (and it does). Soft, quiet and cool rain falling. . . onward.


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: